Tuesday, 4 October 2016

Global Cat Allergy Drugs and Companies Pipeline Review H2 2016


Summary      
 ‘Cat Allergy - Pipeline Review, H2 2016’, provides an overview of the Cat Allergy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Cat Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cat Allergy and features dormant and discontinued projects.
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
- The report provides a snapshot of the global therapeutic landscape of Cat Allergy 
- The report reviews pipeline therapeutics for Cat Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Cat Allergy therapeutics and enlists all their major and minor projects 
- The report assesses Cat Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Cat Allergy
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Cat Allergy 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Cat Allergy pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 
Table of Contents 2 
List of Tables 4 
List of Figures 4 
Introduction 5 
Global Markets Direct Report Coverage 5 
Cat Allergy Overview 6 
Therapeutics Development 7 
Pipeline Products for Cat Allergy - Overview 7 
Cat Allergy - Therapeutics under Development by Companies 8 
Cat Allergy - Pipeline Products Glance 9 
Clinical Stage Products 9 
Early Stage Products 10 
Cat Allergy - Products under Development by Companies 11 
Cat Allergy - Companies Involved in Therapeutics Development 12 
ALK-Abello A/S 12 
Amgen Inc. 13 
Biomay AG 14 
Cat Allergy - Therapeutics Assessment 15 
Assessment by Monotherapy Products 15 
Assessment by Target 16 
Assessment by Mechanism of Action 17 
Assessment by Route of Administration 18 
Assessment by Molecule Type 20 
Drug Profiles 22 
Allergen for Cat Allergy - Drug Profile 22 
Product Description 22 
Mechanism Of Action 22 
R&D Progress 22 
Allergen for Cat Allergy - Drug Profile 23 
Product Description 23 
Mechanism Of Action 23 
R&D Progress 23 
BM-36 - Drug Profile 24 
Product Description 24 
Mechanism Of Action 24 
R&D Progress 24 
tezepelumab - Drug Profile 25 
Product Description 25 
Mechanism Of Action 25 
R&D Progress 25 
Vaccine for Cat Allergy - Drug Profile 27 
Product Description 27 
Mechanism Of Action 27 
R&D Progress 27 
Cat Allergy - Dormant Projects 28 
Cat Allergy - Discontinued Products 29 
Appendix 30 
Methodology 30 
Coverage 30 
Secondary Research 30 
Primary Research 30 
Expert Panel Validation 30 
Contact Us 30 
Disclaimer 31



Contact US:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

No comments:

Post a Comment